Please use this identifier to cite or link to this item:
https://doi.org/10.1158/2326-6066.CIR-21-0129
Title: | BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy | Authors: | Salmon, Avery J Shavkunov, Alexander S Miao, Qi Jarjour, Nicholas N Keshari, Sunita Esaulova, Ekaterina Williams, Charmelle D Ward, Jeffrey P Highsmith, Anna M Pineda, Josue E Taneja, Reshma Chen, Ken Edelson, Brian T Gubin, Matthew M |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology Immunology TRANSCRIPTION FACTOR BHLHE40 ANTITUMOR-ACTIVITY FACTOR DEC1 IFN-GAMMA IMMUNOTHERAPY ANTI-CTLA-4 LYMPHOCYTES BLOCKADE CONTRIBUTES ELEMENTS |
Issue Date: | 1-May-2022 | Publisher: | AMER ASSOC CANCER RESEARCH | Citation: | Salmon, Avery J, Shavkunov, Alexander S, Miao, Qi, Jarjour, Nicholas N, Keshari, Sunita, Esaulova, Ekaterina, Williams, Charmelle D, Ward, Jeffrey P, Highsmith, Anna M, Pineda, Josue E, Taneja, Reshma, Chen, Ken, Edelson, Brian T, Gubin, Matthew M (2022-05-01). BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. CANCER IMMUNOLOGY RESEARCH 10 (5) : 597-611. ScholarBank@NUS Repository. https://doi.org/10.1158/2326-6066.CIR-21-0129 | Abstract: | Immune checkpoint therapy (ICT) using antibody blockade of programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can provoke T cell-dependent antitumor activity that generates durable clinical responses in some patients. The epigenetic and transcriptional features that T cells require for efficacious ICT remain to be fully elucidated. Herein, we report that anti-PD-1 and anti-CTLA-4 ICT induce upregulation of the transcription factor BHLHE40 in tumor antigen-specific CD8+ and CD4+ T cells and that T cells require BHLHE40 for effective ICT in mice bearing immune-edited tumors. Single-cell RNA sequencing of intratumoral immune cells in BHLHE40-deficient mice revealed differential ICT-induced immune cell remodeling. The BHLHE40-dependent gene expression changes indicated dysregulated metabolism, NF-κB signaling, and IFNγ response within certain subpopulations of CD4+ and CD8+ T cells. Intratumoral CD4+ and CD8+ T cells from BHLHE40-deficient mice exhibited higher expression of the inhibitory receptor gene Tigit and displayed alterations in expression of genes encoding chemokines/chemokine receptors and granzyme family members. Mice lacking BHLHE40 had reduced ICT-driven IFNγ production by CD4+ and CD8+ T cells and defects in ICT-induced remodeling of macrophages from a CX3CR1+CD206+ subpopulation to an iNOS+ subpopulation that is typically observed during effective ICT. Although both anti-PD-1 and anti-CTLA-4 ICT in BHLHE40-deficient mice led to the same outcome-tumor outgrowth-several BHLHE40-dependent alterations were specific to the ICT that was used. Our results reveal a crucial role for BHLHE40 in effective ICT and suggest that BHLHE40 may be a predictive or prognostic biomarker for ICT efficacy and a potential therapeutic target. | Source Title: | CANCER IMMUNOLOGY RESEARCH | URI: | https://scholarbank.nus.edu.sg/handle/10635/239167 | ISSN: | 2326-6066 2326-6074 |
DOI: | 10.1158/2326-6066.CIR-21-0129 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
17oct21 MMG v211 Revision Cancer Immunology Research Bhlhe40 manuscript text.pdf | Submitted version | 11.24 MB | Adobe PDF | OPEN | Post-print | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.